List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Development of mitoNEET agonists for the treatment of stroke

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Stroke is the fifth leading cause of death and the leading cause of disability in the United StatesThere remains a critical need for innovative therapeutic approaches that can successfully prevent or reverse brain injury following strokeDysfunction of the mitochondrial biochemistry following ischemic stroke and reperfusion injury contributes to significant neuronal cell losshoweverthe dev ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Osteopontin targeted therapy for primary CNS lymphoma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Abstract Primary central nervous system lymphoma PCNSL is an aggressive brain tumor with a dire unmet therapeutic need It has an overall incidence of per person years and is regarded as an orphan disease with potential for fast track approval Our group made a discovery via gene expression analysis that osteopontin OPN is the most upregulated gene in PCNSL compared to its non CNS ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government